# Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease

## TL;DR

This review discusses new treatment strategies for prostate cancer that becomes resistant to standard therapy, focusing on molecular targets and emerging drugs.

## Contribution

The paper highlights novel therapeutic approaches and molecular targets for castration-resistant prostate cancer.

## Key findings

- Next-generation AR inhibitors like darolutamide show improved safety and efficacy.
- PARP inhibitors are effective for patients with DNA repair gene mutations.
- PSMA-targeted radioligand therapy and HSF1 inhibitors like NXP800 are promising new treatments.

## Abstract

Castration-resistant prostate cancer represents a major clinical challenge, emerging when tumors progress despite standard androgen deprivation therapy. The development of resistance is complex, driven by diverse molecular mechanisms, including androgen receptor (AR) gene amplification and splice variants, as well as AR-independent bypass pathways such as the PI3K/AKT/mTOR and immune checkpoint pathways. These mechanisms involve alternative growth factor signaling, neuroendocrine differentiation, and genetic or epigenetic alterations. This review synthesizes recent advances in understanding these resistance pathways and highlights emerging therapeutic strategies designed to overcome them. Key developments include next-generation AR pathway inhibitors, such as darolutamide, with improved safety profiles; PARP inhibitors for patients with DNA repair gene mutations; and PSMA-targeted radioligand therapy. The therapeutic landscape is also expanding to include novel targets such as the heat shock response, with HSF1 inhibitors like NXP800 in clinical trials for treatment-refractory disease. By targeting this molecular heterogeneity, ongoing research aims to deliver more effective, personalized treatments to improve survival and quality of life for men with advanced prostate cancer.